In July 2025, the FDA granted priority review for TAR-200 as therapy for patients with high-risk nonmuscle invasive bladder ...

Immunocompromised status may negatively affect survival outcomes in patients with bladder cancer, a study suggests.

The 2-year local recurrence-free survival (LRFS) improved from 76.0% without adjuvant RT to 87.1% with it. Disease-free (DFS) ...

Discover a study exploring how bladder cancer organoids advance personalised drug testing, reveal tumour heterogeneity, and ...

Genitourinary cancers require individualized treatment plans based on type, stage, and patient health, utilizing imaging, ...

(Nasdaq: URGN), a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty cancers, today announced the publication of a comprehensive review of the ...

Researchers from the University of Birmingham's Bladder Cancer Research Center have used a new method to detect chemical ...

Circulating tumor cells allow researchers to detect cancer early, provide an accurate prognosis, monitor progression, and ...

The stroma to tumor ratio potentially identifies higher risk bladder cancer tumors and might help guide immunotherapy. Bladder tumors with higher stromal content may have a more immunosuppressive ...

Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...

Deion Sanders had his bladder removed after a cancerous tumor was discovered on it, the Colorado football coach announced in a news conference alongside his medical team on July 28 in Boulder. The ...